Correction: Accelerating influenza research: Vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type H3N2 virus for the human viral challenge model

Daniel J. Fullen; Nicolas Noulin; Andrew Catchpole; Hosnieh Fathi; Edward J. Murray; Alex Mann; Kingsley Eze; Ganesh Balaratnam; Daryl W. Borley; Anthony Gilbert; Rob Lambkin-Williams

ArticleOPEN ACCESS

Correction: Accelerating influenza research: Vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type H3N2 virus for the human viral challenge model

PLoS ONE

DOI: 10.1371/journal.pone.0157211

3Citations

14Readers

Abstract

Fig 11, "Mean mucus weight by day in all subjects in the Human Viral Challenge Model." is a duplicate of Fig 9, "Mean symptom score by day in symptom positive subjects in the Human Challenge Viral Model." Please view the correct Fig 11 here.

Cite

CITATION STYLE

APA

Fullen, D. J., Noulin, N., Catchpole, A., Fathi, H., Murray, E. J., Mann, A., … Lambkin-Williams, R. (2016, June 1). Correction: Accelerating influenza research: Vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type H3N2 virus for the human viral challenge model. PLoS ONE. Public Library of Science. https://doi.org/10.1371/journal.pone.0157211

Correction: Accelerating influenza research: Vaccines, antivirals, immunomodulators and monoclonal antibodies. The manufacture of a new wild-type H3N2 virus for the human viral challenge model

Abstract

Cite

Register to see more suggestions